Ardea Biosciences Inc

Ardea Biosciences — Corporate Update (January 2009)

35 slides from Ardea Biosciences's corporate update, Jan 16, 2009

  1. Slide 1: Company Update

    January 12, 2009 Company Update Barry D. Quart, PharmD President & Chief Executive Officer

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results

  3. Slide 3: Investment Highlights

    3 Investment Highlights Addressing multi-billion-dollar markets Initial efficacy results in gout program in early 2009 Phase 2a results with RDEA806 Phase 1 results with RDEA594 Anticipate initiation of Phase 2 with RDEA594 in 1H09, with results in 2H09 Multiple partnering opportunities in 2009 Clos

  4. Slide 4: Pipeline Addresses Major Markets

    Pipeline Addresses Major Markets RDEA806 RDEA427 RDEA806 RDEA119 RDEA119/ RDEA436 Discovery Preclinical Phase 0/1 Phase 2 A B Phase 3 NNRTI for HIV NNRTI for HIV Gout MEKI for Cancer Inflammation 4 Gout RDEA594 2rd Gen URAT1 MEKI + sorafenib for Cancer RDEA119 Gout

  5. Slide 5: HIV

    HIV Ardea(\))Biosciences

  6. Slide 6: RDEA806 vs. Target Product Profile

    RDEA806 vs. Target Product Profile Highly active against efavirenz-resistant strains High genetic barrier to resistance Better safety profile than efavirenz Reduced CNS toxicity Improved lipid profile Easy to formulate in combination pill Long enough half-life for once daily dosing (10-13 hrs) Can b

  7. Slide 7: HIV Infection Demographics Support Target Product Profile

    HIV Infection Demographics Support Target Product Profile 7 *Estimates Out of 56,300 New Cases in 2006; CDC, New Estimates of HIV Infections

  8. Slide 8: RDEA806 Phase 2A Median Change in Viral Load

    Days RDEA806 Phase 2A Median Change in Viral Load* Last Dose * Viral load reduction censored in 4 patients who reached 50 copies/ml LOQ of assay and some patients started on triple therapy prior to follow-up visit Percent Patients > 1 log Decrease < 400 copies/ml Placebo 0 0 400 mg BID Capsules - Fa

  9. Slide 9: RDEA806 Safety and Tolerability

    RDEA806 Safety and Tolerability No serious adverse events or premature discontinuations Adverse events generally mild (grade 1) with no required intervention; no grade 3/4 adverse events No indication of CNS toxicity and no drug related rash No clinically significant laboratory abnormalities Reducti

  10. Slide 10: Tablet Size Comparisons of Coformulated RDEA806

    Tablet Size Comparisons of Coformulated RDEA806 RDEA806 800 mg + TRUVADA(r) RDEA806 600 mg + TRUVADA(r) ATRIPLA(tm) Sustiva 600 mg + Truvada(r) SUSTIVA(r) 600 mg INTELENCE(tm) 100 mg RDEA806 200 mg 10

  11. Slide 11: No Impact of RDEA806 on Emtricitabine or Tenofovir in Truvada

    No Impact of RDEA806 on Emtricitabine or Tenofovir in Truvada Time (hr) Tenofovir Truvada only dosing Truvada and 800 mg QD RDEA806 x 4 days Time-Concentration Profiles in Plasma Emtricitabine Time (hr) 0.00 0.05 0.10 0.15 0.20 0.25 0 6 12 18 24 30 36 42 48 54 60 66 72 0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.

  12. Slide 12: RDEA427 Has Superior Resistance Profile to Other NNRTIs

    RDEA427 Has Superior Resistance Profile to Other NNRTIs 12

  13. Slide 13: Gout

    GOUT Ardea(()Biosciences

  14. Slide 14: RDEA806 Significantly Reduced Serum Uric Acid in Phase 1 MAD Study

    RDEA806 Significantly Reduced Serum Uric Acid in Phase 1 MAD Study 1 0.5 0 - -0.5 - -1 - -1.5 - -2 - -2.5 Day 0 Day 3 Day 7 Day 10/14 Follow-up Change in SUA (mg/dL) Treatment Day Placebo 500 mg bid 400 mg MR bid 300 mg bid - -3 * * * * * * * * * * p<0.001 Serum UA reduction in 2 patients with hyper

  15. Slide 15: Hyperuricemia/Gout - Unmet Medical Need

    Hyperuricemia/Gout - Unmet Medical Need Gout is caused by abnormally elevated levels of uric acid (>6.8 mg/dL) Painful and debilitating disease Attacks of severe pain/Inflammation Disfiguring nodules (tophi) Kidney damage (nephropathy) Increasing incidence and severity in U.S. (up to 5,000,000 patie

  16. Slide 16: Linear Relationship Between Serum Uric Acid and CRP

    Linear Relationship Between Serum Uric Acid and CRP NHANES III & NHANES 1999-2002 Serum Uric Acid (mg/dl) Log CRP (mg/dL) 2007 ACR Abstract 759 NHANES III n = 18,723 NHANES 99-2002 n = 7,401 Upper 95% CI Lower 95% CI Linear dose-response pattern between sUA and logCRP for sUA concentrations above 4

  17. Slide 17: Competitive Landscape

    Competitive Landscape Allopurinol 40 year old generic xanthine oxidase inhibitor; 21% response rate and 8% SAEs in contemporary study,1 and 0.4% incidence of hypersensitivity, which is 20-25% fatal2 Febuxostat (Takeda) 2nd generation xanthine oxidase inhibitor (more specific than allopurinol) In Pha

  18. Slide 18: Transporters Found in Kidney Proximal Tubule Cells

    Transporters Found in Kidney Proximal Tubule Cells Multiple transporters play important roles in uric acid transport and the occurrence of gout URAT1 previously identified as the most important transporter for uric acid Mutations in ABCG2, SLC17A3, and SLC2A9 recently identified as linked to a highe

  19. Slide 19: RDEA594, a Metabolite of RDEA806, Believed Responsible for Uric Acid Lowering

    <99% Reabsorption Secretion (~50%) Reabsorption (~10% fine tuning) Increased Excretion ~100% of uric acid is initially filtered through glomerular filtration RDEA594, a Metabolite of RDEA806, is Believed to be Responsible for Uric Acid Lowering URAT1 Enomoto; Urat1 identification in Nature May2002 D

  20. Slide 20: RDEA594 Shows Dose Proportional Increases in AUC and Cmax

    RDEA594 Shows Dose Proportional Increases in AUC and Cmax Following Single Oral Doses 20

  21. Slide 21: Mean Change in 24-Hour Serum Uric Acid After Single Doses of RDEA594

    Mean Change in 24-Hour Serum Uric Acid After Single Doses of RDEA594 and Comparators in NHV Fed condition: RDEA806 EC tab 800 mg; RDEA594 sol.100, 400, 600 mg Fasting condition: RDEA594 sol.25, 100, 200 mg; all benzbromarone doses Benzbromarone, a URAT1 transport inhibitor, was a popular drug for th

  22. Slide 22: RDEA594 Phase 2 Dose Response, Safety & Efficacy Study

    Arm 1: RDEA594 Low Dose - 40 pts RDEA594 Phase 2 Dose Response, Safety & Efficacy Study Screening Period Colchicine Treatment 21 days 2 weeks 4 weeks 2 weeks RDEA594-201 Population: gout patients with hyperuricemia (serum uric acid ^8 mg/dL) total of 160 patients in 4 treatment arms Duration: 8 week

  23. Slide 23: RDEA594: Lead Product Candidate for Gout

    RDEA594: Lead Product Candidate for Gout RDEA594 inhibits the URAT1 renal transporter, without significant effects on other renal transporters (no clinically significant interactions with OAT1 & OAT3), and it has no antiviral activity at target levels RDEA594 is a metabolite of RDEA806 in man and al

  24. Slide 24: Cancer and Inflammation

    Cancer and Inflammation Ardea (Biosciences

  25. Slide 25: The Age of Targeted Cancer Treatments

    The Age of Targeted Cancer Treatments Nexavar MEK Ras Raf c-Myc Herceptin, Erbitux Proliferation Angiogenesis Differentiation Apoptosis cPLA2 PDE4 MNK1/2 Elk-1 MAPKAPK1/3 ARRY-142886 (Ph 2) XL518 (Ph 1) RDEA119 (Ph 1)* RTK Bcl-2 Mcl-1 c-Jun Tarceva GF ERK2 ERK2 25 *Only MEK inhibitor in clinic witho

  26. Slide 26: RDEA119 is Potent, Highly Specific MEK Inhibitor

    RDEA119 is Potent, Highly Specific MEK Inhibitor MEK1/2 Enzyme IC50 17-50 nM Cellular pERK EC50 2.5-8.7 nM* >100-fold selectivity in kinase panel of 205 enzymes at 10 µM** *Cell lines: Colo205, A375, A431, HT-29 ** In-house data 1 6 11 16 21 26 31 0 20 40 60 80 100 1 6 11 16 21 26 31 MEK1 & MEK2 MEK

  27. Slide 27: Sorafenib-Resistant Hepatoma Cells Show Remarkable Response to Combination Therapy

    Sorafenib-Resistant Hepatoma Cells Show Remarkable Response to Combination Therapy Percent Cell Death 27

  28. Slide 28: RDEA119 Synergistic in Combination with Many Other Anti-Cancer Agents

    RDEA119 Synergistic in Combination with Many Other Anti-Cancer Agents Potential Combinations Potential Therapeutic Areas Sorafenib Onyx/Bayer Gemcitabine Lilly Temozolomide Schering Lapatinib GSK AKT inhibitors Merck, Others HCC Melanoma Breast Myeloma Pancreas Renal carcinoma NSCLC Thyroid Colon RD

  29. Slide 29: Pharmacokinetics of RDEA119 Following Multiple Doses in Cancer Patients

    Pharmacokinetics of RDEA119 Following Multiple Doses in Cancer Patients Target plasma levels for optimal efficacy from xenograft studies- equals 0.1- 2 ng/ml free drug 29 mg/day QD (Projected)

  30. Slide 30: RDEA119 is Active in Multiple Models of Inflammatory Disease

    RDEA119 is Active in Multiple Models of Inflammatory Disease Rat paw edema model Collagen-induced arthritis in mice and rats (2008 EULAR) Adjuvant-induced Arthritis (2008 EULAR) Pristane-induced arthritis in rats (2008 EULAR) Monosodium urate crystal (uric acid) induced inflammation (2008 ACR) Trini

  31. Slide 31: AIA Rat Study: RDEA119 more Effective than MTX

    AIA Rat Study: RDEA119 more Effective than MTX Days 13 to 28 31

  32. Slide 32: RDEA119-102 Normal Healthy Volunteer Cytokine Pharmacodynamics

    RDEA119-102 Normal Healthy Volunteer Cytokine Pharmacodynamics 2 Hour 32

  33. Slide 33: Financial Position Summary

    Financial Position Summary Statement of Operations (In thousands, except per share data) Nine Months Ended Sept. 30, 2008 Revenue Operating expenses Interest and other income $ 260 44,074 1,485 NET LOSS $(42,329) NET LOSS PER SHARE $(2.98) 17.8 million common shares outstanding; 684,332 warrants pos

  34. Slide 34: Near-Term Anticipated Milestones

    Near-Term Anticipated Milestones Drug Candidate Event Date HIV HIV HIV RDEA806 Phase 2a results (PoC) 2Q08 ? RDEA806 Phase 2b start post-partnering RDEA427 Phase 1 start post-partnering Gout Gout Gout RDEA594 Phase 1 results 1Q09 RDEA806 Phase 2 results (PoC) 1Q09 RDEA594 Phase 2 start 1H09 RDEA594

  35. Slide 35: Ardea Biosciences - Designing Solutions for Serious Diseases

    ) Biosciences” Designing Solutions for Serious Diseases NASDAQ: RDEA

Ardea Biosciences — Corporate Update (January 2009) on 6ix